CardioVascular BioTherapeutics Inc. Email Format

Biotechnology ResearchUnited States11-50 Employees

CardioVascular BioTherapeutics, Inc. operates in the United States as an early-stage biopharmaceutical company focused on advancing biologic drug candidates. Its research targets diseases associated with ischemia, including diabetic wounds, severe ischemic heart disease, peripheral artery disease, erectile dysfunction, and infarct stroke. The organization concentrates on research and development to improve quality of life for people affected by ischemic tissue and organ conditions.
In the biotechnology research industry, CVBT is positioned as a developer pursuing biologic therapies aimed at ischemia-related conditions. Based in the United States, the company operates on a scale typical of smaller biotech firms, with a focus on research and development rather than commercial operations.

Sign up for free to view info

Company overview Employee directory